UBS analyst Ashwani Verma downgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Buy to Neutral and lowers the price target from $85 to $83.
UBS Downgrades Intra-Cellular Therapies to Neutral, Lowers Price Target to $83
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.